Source link : https://www.newshealth.biz/health-news/novo-nordisk-affirms-25-weight-loss-expectation-for-experimental-drug-cagrisema/
LONDON (Reuters) -Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss. Martin Holst Lange, Novo Nordisk’s head of development, made the comments to Reuters after the […]
Author : News Health
Publish date : 2024-11-06 10:54:11
Copyright for syndicated content belongs to the linked Source.